Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts.
Division of Nephrology, Department of Medicine, Houston Methodist Hospital, Houston, Texas.
Am J Kidney Dis. 2024 Jul;84(1):49-61.e1. doi: 10.1053/j.ajkd.2023.11.013. Epub 2024 Jan 23.
RATIONALE & OBJECTIVE: The toxins that contribute to uremic symptoms in patients with chronic kidney disease (CKD) are unknown. We sought to apply complementary statistical modeling approaches to data from untargeted plasma metabolomic profiling to identify solutes associated with uremic symptoms in patients with CKD.
Cross-sectional.
SETTING & PARTICIPANTS: 1,761 Chronic Renal Insufficiency Cohort (CRIC) participants with CKD not treated with dialysis.
Measurement of 448 known plasma metabolites.
The uremic symptoms of fatigue, anorexia, pruritus, nausea, paresthesia, and pain were assessed by single items on the Kidney Disease Quality of Life-36 instrument.
Multivariable adjusted linear regression, least absolute shrinkage and selection operator linear regression, and random forest models were used to identify metabolites associated with symptom severity. After adjustment for multiple comparisons, metabolites selected in at least 2 of the 3 modeling approaches were deemed "overall significant."
Participant mean estimated glomerular filtration rate was 43mL/min/1.73m, with 44% self-identifying as female and 41% as non-Hispanic Black. The prevalence of uremic symptoms ranged from 22% to 55%. We identified 17 metabolites for which a higher level was associated with greater severity of at least one uremic symptom and 9 metabolites inversely associated with uremic symptom severity. Many of these metabolites exhibited at least a moderate correlation with estimated glomerular filtration rate (Pearson's r≥0.5), and some were also associated with the risk of developing kidney failure or death in multivariable adjusted Cox regression models.
Lack of a second independent cohort for external validation of our findings.
Metabolomic profiling was used to identify multiple solutes associated with uremic symptoms in adults with CKD, but future validation and mechanistic studies are needed.
PLAIN-LANGUAGE SUMMARY: Individuals living with chronic kidney disease (CKD) often experience symptoms related to CKD, traditionally called uremic symptoms. It is likely that CKD results in alterations in the levels of numerous circulating substances that, in turn, cause uremic symptoms; however, the identity of these solutes is not known. In this study, we used metabolomic profiling in patients with CKD to gain insights into the pathophysiology of uremic symptoms. We identified 26 metabolites whose levels were significantly associated with at least one of the symptoms of fatigue, anorexia, itchiness, nausea, paresthesia, and pain. The results of this study lay the groundwork for future research into the biological causes of symptoms in patients with CKD.
导致慢性肾脏病(CKD)患者出现尿毒症症状的毒素尚不清楚。我们试图应用非靶向血浆代谢组学分析中互补的统计建模方法,鉴定与 CKD 患者尿毒症症状相关的溶质。
横断面研究。
1761 名未接受透析治疗的慢性肾功能不全队列(CRIC)参与者。
448 种已知血浆代谢物的测量。
通过肾脏病生活质量-36 量表的单项评估,评估尿毒症症状的疲劳、厌食、瘙痒、恶心、感觉异常和疼痛。
采用多变量调整线性回归、最小绝对收缩和选择算子线性回归以及随机森林模型,鉴定与症状严重程度相关的代谢物。经多次比较校正后,在至少 2 种建模方法中选择的代谢物被认为是“总体显著”。
参与者估计肾小球滤过率的平均值为 43ml/min/1.73m,44%的参与者自我认定为女性,41%的参与者为非西班牙裔黑人。尿毒症症状的患病率为 22%至 55%。我们鉴定出 17 种代谢物,其水平升高与至少一种尿毒症症状的严重程度增加相关,9 种代谢物与尿毒症症状严重程度呈负相关。其中许多代谢物与估计肾小球滤过率呈中度相关(皮尔逊相关系数≥0.5),有些代谢物也与多变量调整后的 Cox 回归模型中肾脏衰竭或死亡的风险相关。
缺乏第二个独立的队列来验证我们的研究结果。
代谢组学分析用于鉴定与 CKD 成人尿毒症症状相关的多种溶质,但需要进一步验证和机制研究。
患有慢性肾脏病(CKD)的个体常出现与 CKD 相关的症状,传统上称为尿毒症症状。CKD 可能导致许多循环物质的水平发生改变,这些物质反过来又会引起尿毒症症状;然而,这些溶质的身份尚不清楚。在这项研究中,我们使用 CKD 患者的代谢组学分析来深入了解尿毒症症状的病理生理学。我们鉴定出 26 种代谢物,其水平与疲劳、厌食、瘙痒、恶心、感觉异常和疼痛等至少一种症状显著相关。本研究为进一步研究 CKD 患者症状的生物学原因奠定了基础。